Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Quick facts
Phase 3 pipeline
- Matching Placebo to Fidaxomicin · Infectious Disease
This is a placebo formulation designed to match the appearance and administration characteristics of fidaxomicin for blinded clinical trial comparison. - PAR-101/OPT-80 · Infectious Disease
PAR-101/OPT-80 is a non-systemic antibiotic that binds to bacterial RNA polymerase to inhibit Clostridioides difficile growth in the colon.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI brief
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates RSS
Frequently asked questions about Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
What is Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s pipeline?
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Matching Placebo to Fidaxomicin, PAR-101/OPT-80.
Related
- Sector hub: All tracked pharma companies